|
CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE ESSAIS TESTANT LE ROLE DE LA DOSE DE CISPLATINE
|
|
référence |
Schéma de chimiothérapie |
n |
(st IV) |
% R0 |
p |
SM |
p |
Gralla,
1981 |
I. CDDP (120 mg/m2) +VDS |
41 |
|
40 |
NS |
|
NS |
II. CDDP (60 mg/m2) +VDS |
40 |
|
46 |
|
Klastersky,
1986 |
CDDP-VP16 |
|
|
|
NS |
|
NS |
I. 120 mg/m2 |
116 |
(63) |
29 |
28 s |
II. 60 mg/m2 |
125 |
(76) |
25 |
33 s |
Shinkai,
1986 |
I. CDDP (120 mg/m2) +VDS |
24 |
(19) |
39 |
NS |
9 m |
|
II. CDDP (80 mg/m2) +VDS |
21 |
(16) |
33 |
10,8 m |
Gandara
1993 |
CDDP |
|
|
|
NS |
|
NS |
I. 2 x 100 mg/m2 |
108 |
(108) |
14 |
5,3 m |
II. 2 x 50 mg/m2 |
105 |
(105) |
12 |
6,9 m |
Sculier,
2000 |
Ifo – MMC |
|
|
|
NS |
|
NS |
I.CDDP 50 mg/m² |
147 |
(143) |
27% |
28 s |
II. CDDP 60 mg/m² + CBDCA (200 mg/m²) |
150 |
(145) |
33% |
32 s |
Références
(1) Gralla RJ, Casper ES, Kelsen DP, Braun DWJ, Dukeman ME, Martini N et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95(4):414-420.
(2) Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 1986; 4(12):1780-1786.
(3) Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tominaga K, Sakurai M et al. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res 1986; 77(8):782-789.
(4) Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11(5):873-878.
(5) Sculier JP, Lafitte JJ, Paesmans M, Thiriaux J, Alexopoulos CG, Baumohl J et al. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer 2000; 83(9):1128-1135.
|